Lucentis for Central Retinal Vein Occlusion (CRVO)

This study has been completed.
Sponsor:
Collaborator:
Genentech
Information provided by:
California Retina Consultants
ClinicalTrials.gov Identifier:
NCT00406796
First received: November 29, 2006
Last updated: December 10, 2013
Last verified: December 2013

November 29, 2006
December 10, 2013
January 2006
September 2008   (final data collection date for primary outcome measure)
The primary objective is to determine the proportion of subjects in each group ( 0.3, 0.5 mg ) gaining 15 or more letters at month 6 and 12 (ETDRS visual refraction at 4 meters) and to determine if a difference exists between the high and low dose. [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
The primary objective is to determine the proportion of subjects in each group ( 0.3 and 0.5 mg ) gaining 15 or more letters at month 6 and 12 (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between
Complete list of historical versions of study NCT00406796 on ClinicalTrials.gov Archive Site
  • To determine the safety and tolerability of ranibizumab in the treatment of macular edema associated with CRVO in each group [ Time Frame: 6 and 12 months ] [ Designated as safety issue: Yes ]
  • To determine the proportion of subjects in each group gaining 15 or more letters at month 3, 6, 9 & 12 as compared to baseline (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between the groups [ Time Frame: 3, 6, 9, and 12 months ] [ Designated as safety issue: No ]
  • Change in central retinal thickness from baseline as measured by OCT at months 3, 6, 9 and 12 [ Time Frame: 3,6,9, and 12 months ] [ Designated as safety issue: No ]
  • To determine the proportion of subjects in each group losing 15 or more letters at months 3,6,9,12 as compared to baseline (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between the groups. [ Time Frame: 3, 6, 9, and 12 months ] [ Designated as safety issue: No ]
  • To determine the proportion of subjects in each group losing 30 or more letters at months 3,6,8,12 as compared to baseline (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between the groups. [ Time Frame: 3, 6, 9, and 12 months ] [ Designated as safety issue: No ]
  • To determine if changes in best-corrected visual acuity are correlated with changes in total macular volume, center point thickness, and/or central 1mm subfield thickness. [ Time Frame: Months 1-12 ] [ Designated as safety issue: No ]
  •  To determine the safety and tolerability of ranibizumab in the treatment of macular edema associated with CRVO in each group
  •  To determine the proportion of subjects in each group gaining 15 or more letters at month 3, 6, 9 & 12 as compared to baseline (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between the groups
  •  Change in central retinal thickness from baseline as measured by OCT at months 3, 6, 9 and 12
  •  To determine the proportion of subjects in each group losing 15 or more letters at months 3,6,9,12 as compared to baseline (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between the groups.
  •  To determine the proportion of subjects in each group losing 30 or more letter at months 3,6,8,12 as compared to baseline (ETDRS visual refraction at 4 meters) and to determine if a statistically significant difference exists between the groups.
Not Provided
Not Provided
 
Lucentis for Central Retinal Vein Occlusion (CRVO)
FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease

The purpose of this study is to determine whether ranibizumab will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).

Retinal Venous Occlusive disease is the second only to diabetic retinopathy as a major cause of blindness associated with retinal vascular disease. Macular edema is a major cause of vision loss in patients presenting with central abd hemi vein occlusions. Currently, there is no proven treatment to address macular edema in these patients. In the past laser photocoagulation has been used, but was found to offer no visual benefits over the natural history in the treatment of macular edema associated with CRVO. Investigators have demonstrated in case reports that intravitreal triamcinolone (Kenalog) may result in the reduction in macular edema, leading to visual improvement in some patients with CRVO. Triamcinolone is relatively well tolerated in many patients, but its use is associated with significant risk of elevated intraocular pressure, cataract, and intraocular infection.

Ranibizumab (rhuFab V2, an anti-VEGF agent, is a potent inhibitor of vascular permeability, with the potential to reduce retinal vascular leakage and diminish macular edema. In addition, as an anti-VEGF agent, it may also inhibit neovascularization of the iris, a frequent complication of ischemic central retinal vein occlusion. Ranibizumab use as an intravitreal agent does carry the risk of intraocular infection but probably carries very low risk of glaucoma or cataract formation, making it a potentially safer pharmacologic treatment for CRVO associated macular edema as compared to triamcinolone

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Central Retinal Vein Occlusion
Drug: Ranibizumab
0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
Other Name: Lucentis
  • Active Comparator: 1
    0.5mg Ranibizumab
    Intervention: Drug: Ranibizumab
  • Active Comparator: 2
    0.3mg Ranibizumab
    Intervention: Drug: Ranibizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
October 2010
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Clinical evidence of perfused central retinal vein occlusion. A central retinal vein occlusion (CRVO) is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head.
  • Central macular edema present on clinical examination and OCT testing with a central point thickness > 250 microns
  • Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
  • Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography

Exclusion Criteria:

  • Pregnancy (positive pregnancy test) or known to be pregnant, also premenopausal women not using adequate contraception.
  • Participation in another simultaneous ocular investigation or trial
  • Patient with uncontrolled hypertension
  • Patient has a condition that, in the opinion of the investigator would preclude participation in the study (i.e. chronic alcoholism, drug abuse)
  • Patient has significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
  • Exam or OCT reveals evidence of vitreoretinal interface abnormality that may be contributing to the macular edema
  • Eye that in the investigator has no chance of improvement in visual acuity following resolution of macular edema (i.e subretinal fibrosis or geographic atrophy)
  • Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (i.e AMD, uveitis, Irvine-Gas)
  • Evidence of neovascularization of the iris or retina (presence of ischemic CRVO)
  • Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
  • History of Grid/Focal laser or Panretinal laser in the study eye
  • History of vitreous surgery in the study eye
  • History of use of intravitreal, peribulbar, or retrobulbar steroids within six months of the study.
  • History of Cataract Surgery within 6 months of enrollment.
  • History of YAG capsulotomy within 2 months of the surgery.
  • Visual acuity <20/400 in the fellow eye
  • Uncontrolled Glaucoma, pressure >30 despite treatment with glaucoma medications.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00406796
FVF3565s
Yes
Dante J Pieramici, California Retina Consultants and Research Foundation
California Retina Consultants
Genentech
Principal Investigator: Dante J Pieramici, M.D. California Retina Consultants
California Retina Consultants
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP